No Data
No Data
Express News | MaxCyte Signs License Agreement With Legend Biotech, Under Which Legend Obtains Non-Exclusive Worldwide License To Use MaxCyte's Flow Electroporation And ExPERT Platform; MaxCyte Eligible For Fees And Miletones
Express News | MaxCyte Inc - Will Be Eligible to Receive Annual Licensing Fees and Milestones From Legend Biotech During Clinical Development
Express News | MaxCyte Inc - Under Terms, Legend Biotech Obtains a Non-Exclusive Worldwide License to Use Co's Flow Electroporation Technology and Expert Platform
Express News | MaxCyte Signs Strategic Platform License Agreement With Legend Biotech to Accelerate Cell Therapy Discovery and Development
Analysts Offer Insights on Healthcare Companies: Daré Bioscience (DARE), Legend Biotech (LEGN) and Singular Genomics Systems (OMIC)
Legend Expects to Log Profit in 2026
Nasdaq-listed biotechnology company Legend Biotech expects to log a profit in 2026, according to a Monday filing by parent company Genscript Biotech (HKG:1548) on the Hong Kong bourse. Legend Biotech
No Data